Leerink Partnrs Issues Pessimistic Outlook for GPCR Earnings

Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) - Equities researchers at Leerink Partnrs lowered their FY2025 earnings per share estimates for Structure Therapeutics in a research report issued on Thursday, May 8th. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings of $1.78 per share for the year, down from their prior estimate of $1.80. The consensus estimate for Structure Therapeutics' current full-year earnings is ($0.82) per share. Leerink Partnrs also issued estimates for Structure Therapeutics' FY2029 earnings at $0.97 EPS.

Other analysts also recently issued reports about the company. Citigroup began coverage on Structure Therapeutics in a research note on Friday, May 2nd. They issued a "buy" rating and a $60.00 target price for the company. HC Wainwright cut their price target on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a report on Monday. Finally, William Blair assumed coverage on Structure Therapeutics in a report on Friday, February 28th. They set an "outperform" rating for the company. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $78.00.

Structure Therapeutics Stock Down 0.3%

GPCR traded down $0.07 during midday trading on Monday, hitting $23.82. The company had a trading volume of 1,295,933 shares, compared to its average volume of 930,949. The stock's 50 day moving average price is $20.98 and its 200 day moving average price is $26.75. Structure Therapeutics has a 52 week low of $13.22 and a 52 week high of $62.74. The company has a market capitalization of $1.37 billion, a price-to-earnings ratio of -32.19 and a beta of -1.69.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03).

Institutional Trading of Structure Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GPCR. Barclays PLC boosted its position in shares of Structure Therapeutics by 64.5% during the third quarter. Barclays PLC now owns 81,138 shares of the company's stock valued at $3,562,000 after buying an additional 31,815 shares during the last quarter. Principal Financial Group Inc. lifted its stake in Structure Therapeutics by 230.0% during the 3rd quarter. Principal Financial Group Inc. now owns 545,359 shares of the company's stock valued at $23,936,000 after acquiring an additional 380,115 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Structure Therapeutics by 302.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 33,936 shares of the company's stock worth $1,489,000 after acquiring an additional 25,500 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Structure Therapeutics by 4,155.6% in the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock worth $31,000 after acquiring an additional 1,122 shares in the last quarter. Finally, FNY Investment Advisers LLC purchased a new stake in shares of Structure Therapeutics in the fourth quarter valued at about $40,000. 91.78% of the stock is owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.